NEU 3.17% $20.86 neuren pharmaceuticals limited

Ann: Q2 2023 quarterly activity and cash flow report, page-10

  1. 41 Posts.
    lightbulb Created with Sketch. 8
    From the SEC filing from Acadia (my formatting):


    In addition, pursuant to the License Agreement, Neuren granted to the Company a worldwide, exclusive license to develop and commercialize any product developed by or on behalf of Neuren or the Company containing a NNZ-2591 compound as an active ingredient (a “NNZ-2591 Product”) for the treatment of Rett syndrome and Fragile X syndrome (the “Acadia NNZ-2591 Field”). Neuren may conduct development and commercialization of NNZ-2591 outside of the Acadia NNZ-2591 Field.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.86
Change
0.640(3.17%)
Mkt cap ! $2.666B
Open High Low Value Volume
$20.45 $21.10 $20.39 $9.299M 447.5K

Buyers (Bids)

No. Vol. Price($)
1 671 $20.85
 

Sellers (Offers)

Price($) Vol. No.
$20.86 262 1
View Market Depth
Last trade - 16.10pm 26/06/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.